A. Kapoun

发表

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors

J. Heymach, P. LoRusso, A. Patnaik, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Antitumor Activity of TGF-β, Inhibitor is Dependent on the Microenvironment

Lingyun Li, G. Schreiner, S. Medicherla, 2007 .

A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.

R. Burger, M. Morgan, P. Sabbatini, 2019, Gynecologic oncology.

Role of p38 mitogen-activated protein kinase in ozone-induced airway hyperresponsiveness and inflammation.

I. Adcock, K. Chung, A. Durham, 2008, European journal of pharmacology.

A Selective p 38 Mitogen-Activated Protein Kinase Inhibitor Reverses Cartilage and Bone Destruction in Mice with Collagen-Induced Arthritis

H. Genant, Yebin Jiang, S. Medicherla, 2006 .

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

M. Fischer, J. Lewicki, A. Gurney, 2012, Proceedings of the National Academy of Sciences.

Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-XL, Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo

T. Hideshima, K. Anderson, G. Schreiner, 2006, Leukemia.

Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.

T. Hideshima, K. Anderson, G. Schreiner, 2006, Leukemia.

B-Type Natriuretic Peptide Exerts Broad Functional Opposition to Transforming Growth Factor-&bgr; in Primary Human Cardiac Fibroblasts: Fibrosis, Myofibroblast Conversion, Proliferation, and Inflammation

G. Schreiner, A. Protter, A. Kapoun, 2004, Circulation research.

Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.

M. Fischer, J. Lewicki, A. Gurney, 2011, Cancer research.

Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors

Nicholas J. Wang, P. Spellman, L. V. van't Veer, 2012, Breast Cancer Research and Treatment.

Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer

R. Brachmann, J. Diamond, J. O’Shaughnessy, 2020, Breast Cancer Research and Treatment.

Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).

A. Chiang, L. Hart, M. Pietanza, 2015 .

Abstract 1907: Wnt pathway antagonist OMP-54F28 (FZD8-Fc) inhibits tumor growth and reduces tumor-initiating cell frequency in patient-derived hepatocellular carcinoma and ovarian cancer xenograft models

M. Fischer, J. Lewicki, A. Gurney, 2014 .

Abstract A30: Predictive and pharmacodynamic biomarkers of vantictumab (OMP-18R5; anti-Frizzled) in non-small cell lung cancer

M. Fischer, J. Lewicki, T. Hoey, 2015 .

p38α Mitogen-Activated Protein Kinase Inhibition Improves Cardiac Function and Reduces Myocardial Damage in Isoproterenol-Induced Acute Myocardial Injury in Rats

G. Schreiner, A. Protter, A. Kapoun, 2004, Journal of cardiovascular pharmacology.

Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)

J. Berlin, H. Lenz, F. Cattaruzza, 2016 .

B-Type natriuretic peptide inhibited angiotensin II-stimulated cholesterol biosynthesis, cholesterol transfer, and steroidogenesis in primary human adrenocortical cells.

A. Protter, A. Kapoun, Andrew Lam, 2007, Endocrinology.

Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression.

S. Rennard, Ying Wang, F. Wen, 2006, Molecular Pharmacology.

A Selective p38α Mitogen-Activated Protein Kinase Inhibitor Reverses Cartilage and Bone Destruction in Mice with Collagen-Induced Arthritis

H. Genant, Yebin Jiang, S. Medicherla, 2006, Journal of Pharmacology and Experimental Therapeutics.

A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.

H. Genant, Yebin Jiang, S. Medicherla, 2006, The Journal of pharmacology and experimental therapeutics.

First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors.

David C. Smith, A. Tolcher, K. Papadopoulos, 2013 .

J Am Soc Nephrol 14: 338–351, 2003 Blockade of p38 � MAPK Ameliorates Acute Inflammatory Renal Injury in Rat Anti-GBM Glomerulonephritis

R. Atkins, D. Nikolic-Paterson, G. Tesch, 2022 .

Anti-DLL4 HasBroad SpectrumActivityinPancreatic Cancer DependentonTargetingDLL4-NotchSignalinginBothTumor and Vasculature Cells

Edward J. Kim, M. Fischer, J. Lewicki, 2012 .

Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs

D. Brenner, J. Lachowicz, A. Gurney, 2020, PloS one.

A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) +/- nab-paclitaxel in patients with pancreatic cancer.

A. Carrato, M. Hidalgo, J. Dupont, 2016 .

Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with paclitaxel (P) in patients (pts) with 1st- to 3rd-line metastatic HER2-negative breast cancer (BC).

R. Brachmann, J. Diamond, J. O’Shaughnessy, 2016 .

p38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells.

Hui Wang, A. Protter, A. Kapoun, 2004, Journal of molecular and cellular cardiology.

A functional analysis of 5', intronic and promoter regions of the homeotic gene proboscipedia in Drosophila melanogaster.

T. Kaufman, A. Kapoun, 1995, Development.

p38α-Selective Mitogen-Activated Protein Kinase Inhibitor SD-282 Reduces Inflammation in a Subchronic Model of Tobacco Smoke-Induced Airway Inflammation

S. Medicherla, A. Protter, A. Kapoun, 2008, Journal of Pharmacology and Experimental Therapeutics.

Satyanarayana Medicherla, Jing Ying Ma, Ruban Mangadu, Yebin

H. Genant, A. Protter, A. Kapoun, 2006 .

Abstract 1549: Development and validation of a biomarker for prospective selection of Notch1 activation in patients with certain advanced solid tumors in a first-in-human phase1 study of the cancer stem cell targeting antibody OMP-52M51 (anti-Notch1)

J. Lewicki, T. Hoey, S. Anderson, 2015 .

A phase Ib study of the anti-cancer stem cell agent demcizumab (DEM) & gemcitabine (GEM) +/- paclitaxel protein bound particles (nab-paclitaxel) in pts with pancreatic cancer.

A. Carrato, M. Hidalgo, J. Dupont, 2015 .

Abstract B48: A first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors.

P. LoRusso, A. Patnaik, P. Munster, 2013 .

A first-in-human phase I study to evaluate the fully human monoclonal antibody OMP-59R5 (anti-Notch2/3) administered intravenously to patients with advanced solid tumors.

David C. Smith, A. Tolcher, J. Dupont, 2012 .

Regulatory regions of the homeotic gene proboscipedia are sensitive to chromosomal pairing.

T. Kaufman, A. Kapoun, 1995, Genetics.

Transforming Growth Factor-β Receptor Type 1 (TGFβRI) Kinase Activity but Not p38 Activation Is Required for TGFβRI-Induced Myofibroblast Differentiation and Profibrotic Gene Expression

S. Rennard, Ying Wang, F. Wen, 2006, Molecular Pharmacology.

Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.

M. Weller, W. Wick, A. Protter, 2007, Neuro-oncology.

Pharmacological Properties of SD-282 – An α-Isoform Selective Inhibitor for p38 MAP Kinase

S. Medicherla, A. Protter, A. Kapoun, 2008, Pharmacology.

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

M. Fischer, J. Lewicki, A. Gurney, 2015, Clinical Cancer Research.

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

M. Hidalgo, M. Millward, B. Markman, 2018, Targeted Oncology.

Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies

I. Flinn, P. Porcu, J. Dupont, 2016 .

A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors

David C. Smith, A. Tolcher, K. Papadopoulos, 2018, Investigational new drugs.

A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors

David C. Smith, A. Jimeno, J. Diamond, 2018, Investigational New Drugs.

A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors

Branimir Sikic, David C. Smith, Rashmi Chugh, 2014, Clinical Cancer Research.

Intratumoral heterogeneity generated by Notch signaling promotes small cell lung cancer

K. Garcia, M. Fischer, J. Sage, 2017, Nature.

RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations

M. Fischer, T. Hoey, F. Cattaruzza, 2017, Scientific Reports.

Abstract A030: Biomarker study of vantictumab plus paclitaxel in HER2- breast cancer patients

J. Lewicki, F. Cattaruzza, G. Argast, 2018 .

WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death

M. Fischer, J. Lewicki, A. Gurney, 2017, Science Advances.

Abstract 4367: Discovery and evaluation of pharmacodynamic and predictive biomarkers for anti-RSPO3, a treatment that reduces tumor growth and cancer stem cell frequency in patient derived xenograft tumor models

M. Fischer, J. Lewicki, A. Gurney, 2015 .

Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer

H. Lenz, R. Brachmann, W. Messersmith, 2020, Clinical Cancer Research.

A first-in-human phase 1 study of anticancer stem cell agent OMP-54F28 (FZD8-Fc), decoy receptor for WNT ligands, in patients with advanced solid tumors.

David C. Smith, A. Jimeno, R. Brachmann, 2014 .

A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

A. Bullock, J. Bendell, J. Dupont, 2019, Cancer medicine.

A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer

J. Berlin, H. Lenz, W. Messersmith, 2019, Investigational New Drugs.

Recombinant Vascular Endothelial Growth Factor 121 Attenuates Hypertension and Improves Kidney Damage in a Rat Model of Preeclampsia

N Stephen Pollitt, Ying Zhang, Frederick Sannajust, 2007, Hypertension.

Alcohol Dehydrogenase and Alcohol Tolerance in Drosophila melanogaster

B. W. Geer, A. Kapoun, P. W. Heinstra, 1990 .

Abstract 4652: Effects of anti-DLL4 treatment on non-small cell lung cancer (NSCLC) human xenograft tumors

M. Fischer, J. Lewicki, A. Gurney, 2016 .

Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells

Edward J. Kim, M. Fischer, J. Lewicki, 2012, Clinical Cancer Research.

Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor.

M. Kolb, J. Gauldie, A. Protter, 2005, American journal of respiratory and critical care medicine.

Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

M. Bitzer, A. Verma, S. Kambhampati, 2008, Blood.

Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS. Commentary

M. Bitzer, A. Verma, S. Kambhampati, 2008 .

Ca2+/calmodulin-dependent kinase II triggers cell membrane injury by inducing complement factor B gene expression in the mouse heart.

R. Weiss, J. Thurman, T. Blackwell, 2009, The Journal of clinical investigation.

Heterogeneous activation of the TGFβ pathway in glioblastomas identified by gene expression-based classification using TGFβ-responsive genes

Xie L Xu, A. Kapoun, Ann M Kapoun, 2009, Journal of Translational Medicine.

A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors

David C. Smith, A. Jimeno, R. Brachmann, 2017, Clinical Cancer Research.

A Phase 1a/b Open‑Label, Dose‑Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.

J. Bendell, J. Strickler, L. Faoro, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Abstract 2834: Anti-DLL4 treatment inhibits melanoma tumor growth, recurrence, metastases, and reduces frequency of cancer stem cells in a clinically relevant tumor model in NOD/SCID mice

M. Fischer, J. Lewicki, A. Gurney, 2011 .

Altered patterns of gene expression in response to myocardial infarction.

L. Stanton, G. Schreiner, A. Protter, 2000, Circulation research.

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

G. Roodman, N. Kurihara, G. Schreiner, 2006, Experimental cell research.

p 38 α Selective MAP kinase inhibitor , SD-282 , reduces inflammation in a sub-chronic model of tobacco smoke-induced airway inflammation

S. Medicherla, A. Protter, A. Kapoun, 2007 .

Inhibition of Transforming Growth Factor β Signaling Reduces Pancreatic Adenocarcinoma Growth and Invasiveness

Alison Murphy, Lingyun Li, S. Medicherla, 2007, Molecular Pharmacology.

Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.

Lingyun Li, G. Schreiner, S. Medicherla, 2007, Anticancer research.

Phase Ib study of WNT inhibitor ipafricept (IPA) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (mPC).

H. Lenz, R. Brachmann, W. Messersmith, 2019, Journal of Clinical Oncology.

Molecular control of the induction of alcohol dehydrogenase by ethanol in Drosophila melanogaster larvae.

B. W. Geer, A. Kapoun, S. McKechnie, 1990, Genetics.

Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.

M. Fischer, J. Lewicki, A. Gurney, 2016, Cancer research.

Cancer Therapy : Preclinical Anti-DLL 4 HasBroad SpectrumActivity in Pancreatic Cancer DependentonTargetingDLL 4-NotchSignaling inBothTumor and Vasculature Cells

Edward J. Kim, M. Fischer, J. Lewicki, 2012 .

Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency

M. Fischer, J. Lewicki, A. Gurney, 2015 .

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors

Jing Wang, J. Lee, A. Futreal, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).

A. Bullock, J. Bendell, J. Dupont, 2017 .

Abstract 3129: Predictive biomarker identification for response to vantictumab (OMP-18R5; anti-Frizzled) using primary patient-derived human pancreatic tumor xenografts

M. Fischer, J. Lewicki, A. Gurney, 2016 .

Abstract B79: A first-in-human Phase 1 study of anti-cancer stem cell (CSC) agent OMP-54F28 (FZD8-Fc) targeting the WNT pathway in patients with advanced solid tumors.

David C. Smith, A. Jimeno, R. Brachmann, 2013 .

Transforming Growth Factor-β Receptor Type 1 (TGFβRI) Kinase Activity but Not p38 Activation Is Required for TGFβRI-Induced Myofibroblast Differentiation and Profibrotic Gene Expression

S. Rennard, Ying Wang, F. Wen, 2006, Molecular Pharmacology.

Preferential activation of Fgf8 by proviral insertion in mammary tumors of Wnt1 transgenic mice

G. Shackleford, A. Kapoun, 1997, Oncogene.

induced myofibroblast differentiation and pro-fibrotic gene expression

S. Rennard, Ying Wang, F. Wen, 2006 .

Abstract 404: Development of a RSPO3 CLIA-validated assay as a predictive biomarker for response to anti-RSPO3 antibody treatment in patients with solid tumors

M. Fischer, J. Lewicki, A. Gurney, 2016 .

Abstract C42: Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors

A. Tolcher, A. Shields, A. Patnaik, 2015 .

Abstract 3728: Anti-Notch1 antibody (OMP-52M51) impedes tumor growth and cancer stem cell frequency (CSC) in a chemo-refractory breast cancer xenograft model with an activating Notch1 mutation and screening for activated Notch1 across multiple solid tumor types.

L. Esserman, J. Lewicki, A. Gurney, 2013 .

1530PDResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)

C. Rudin, A. Chiang, T. Burns, 2017 .

Abstract 255: Dual targeting of Delta-like ligand 4 (DLL4) and programmed death 1(PD1) inhibits tumor growth and generates enhanced long-term immunological memory

J. Lewicki, A. Gurney, T. Hoey, 2015 .

Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).

L. Smith, J. Bendell, J. Dupont, 2014 .

Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)

J. Berlin, H. Lenz, F. Cattaruzza, 2016 .

Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.

M. Fischer, J. Lewicki, A. Gurney, 2011, Cancer research.

A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors

David C. Smith, A. Jimeno, J. Diamond, 2018, Investigational New Drugs.

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

M. Hidalgo, M. Millward, B. Markman, 2018, Targeted Oncology.

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

M. Fischer, J. Lewicki, A. Gurney, 2015, Clinical Cancer Research.

A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors

David C. Smith, B. Sikic, G. Manikhas, 2014, Clinical Cancer Research.

Therapeutic targeting of tumor-derived R-spondin attenuates β-catenin signaling and tumorigenesis in multiple cancer types

J. Lewicki, A. Gurney, T. Hoey, 2015 .

p38α Mitogen-Activated Protein Kinase Inhibition Improves Cardiac Function and Reduces Myocardial Damage in Isoproterenol-Induced Acute Myocardial Injury in Rats

A. Protter, A. Kapoun, S. Chakravarty, 2004, Journal of cardiovascular pharmacology.

Phase 1b of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with carboplatin (C) and paclitaxel (P) in recurrent platinum-sensitive ovarian cancer (OC).

M. Fischer, P. Sabbatini, F. Cattaruzza, 2016 .